Uterine Leiomyoma Associated Pain Treated Effectively by Relugolix Combination Therapy

A new study in Obstetrics & Gynecology journal points that Relugolix-CT was effective and significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain.

The effect of once-daily relugolix combination therapy was assessed in a combination of relugolix-CT: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, compared with placebo on moderate-to-severe pain in women with uterine leiomyomas and heavy menstrual bleeding.

A multinational, double-blind, 24-week, randomized, phase 3 studies "LIBERTY 1 and 2" were conducted in premenopausal women with uterine leiomyoma–associated heavy menstrual bleeding. A predefined secondary objective was to determine the effect of Relugolix-CT on moderate-to-severe uterine leiomyoma–associated pain in the pain subpopulation. The key secondary endpoint was defined as the proportion of women achieving minimal-to-no uterine leiomyoma–associated pain at week 24; menstrual and nonmenstrual pain were evaluated in prespecified secondary analyses. Treatment comparisons were performed in the pooled LIBERTY 1 and 2 pain subpopulation using the Cochran-Mantel-Haenszel test stratified by baseline menstrual blood loss volume.